• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.06 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup
October 09, 2025
ACADIA Pharmaceuticals shows strong EPS and revenue growth with a positive technical setup, making it a compelling growth stock candidate. 
Via Chartmill
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
October 03, 2025
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant... 
Via MarketMinute
Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock
September 29, 2025
In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish. 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity
September 29, 2025
Discover ACADIA PHARMACEUTICALS (ACAD), a strong affordable growth stock with impressive earnings, solid financials, and a reasonable valuation in the biotech sector. 
Via Chartmill
Earnings Scheduled For August 6, 2025
August 06, 2025
 
Via Benzinga
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts
June 05, 2025
 
Via Benzinga
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
September 24, 2025
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook. 
Via Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
September 24, 2025
The companies are working on treatments for a rare, genetic disease that can cause excessive hunger. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 24, 2025
 
Via Benzinga
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
September 24, 2025
The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials. 
Via Stocktwits
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Technical Setup for Potential Breakout
September 19, 2025
ACADIA Pharmaceuticals (ACAD) shows strong technical momentum with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders. 
Via Chartmill
Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts
September 09, 2025
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Emerges as a Top Affordable Growth Stock
September 08, 2025
ACADIA Pharmaceuticals (ACAD) offers strong growth metrics and a reasonable valuation within the biotech sector, making it a top affordable growth stock pick. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential
August 18, 2025
ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential
August 16, 2025
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick. 
Via Chartmill
Acadia (ACAD) Q2 Revenue Rises 9%
August 06, 2025
Via The Motley Fool
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates
August 06, 2025
Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2025
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation
July 25, 2025
ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
What Analysts Are Saying About ACADIA Pharmaceuticals Stock
July 24, 2025
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
July 22, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors. 
Via Chartmill
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
July 04, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth... 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
June 24, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities. 
Via Chartmill
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know
June 23, 2025
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock
June 12, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth... 
Via Chartmill
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
June 06, 2025
Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent. 
Via Benzinga
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
May 22, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting stock for growth investors. 
Via Chartmill
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals
May 19, 2025
 
Via Benzinga
Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals
May 19, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap